Why Did MedReleaf Corp. Recently Underperform its Peers?

MedReleaf Corp. (TSX:LEAF) might have underperformed its marijuana peers recently, but the stock could still perform better.

| More on:

MedReleaf Corp.’s (TSX:LEAF) stock price is currently underperforming its top Canadian marijuana peers, and the company’s market capitalization has been shrinking of late. MedReleaf has fallen from being the second-biggest cannabis play behind Canopy Growth Corp. (TSX:WEED) to fourth place.

The company currently ranks behind Aphria Inc. (TSX:APH) and Aurora Cannabis Inc. (TSX:ACB) going into the weekend of July 15.

MedReleaf’s market cap stood at $741 million at the $8.20 closing share price for the weekend, while the equity in Aphria was valued at $795.73 million, and Aurora’s market cap had shot up to $865 million, while Canopy lead at $1.29 billion.

Excluding the attempted price recovery from the deep discount from the $9.50 initial public offering (IPO) price on the first trading day, during which the stock commenced trading around $7.50, the company has gone on to shed shareholder value and has underperformed the other big cannabis growers, as shown in the graph below.

Could it be because of the falling margins?

It is possible that investors were put off by the falling margins reported in MedReleaf’s latest financial results after being expected to continue the stellar performance during the company’s private days before the IPO.

However, some investors might feel that the IPO was overpriced at $9.50 considering that the listing was done during a protracted general cooling off of the marijuana sector. This could be evidenced by the deep 21% discount to $7.50 on the first trading day.

I wouldn’t want to believe so though, but if that is the case, then the stock might touch the $7.50 price point again some time.

Something else could explain MedReleaf’s underperformance.

If we set the overpriced IPO thesis aside and forgive the disappointing falling margins (even Canopy disappointed on this front), there are just two other possible reasons left to ponder.

MedReleaf could have underperformed on the back of positive market news that has been boosting its competitors’ stocks while it suffers from being relatively unknown to investors.

Aphria and Aurora stock prices have shown promise with details of international expansion programs.

Aphria also reported faster revenue growth and stronger operating earnings growth than MedReleaf earnings, which showed declining margins.

Furthermore, Aphria has shown some massive productive efficiency improvements as we head towards a bigger recreational market. The company reported the lowest cash costs per gram in the whole industry and had its revenues boosted by oil sales.

Aurora’s possible success in obtaining a local production licence in the promising Germany market could have buoyed the stock, while Canopy is still an investor favourite to lead the local recreational market after its local expansion program update.

Meanwhile, there hasn’t been much talk from MedReleaf, which is still a relatively unknown stock. The company’s stock might have been hoarded by traders who might have expected the company to maintain its high margins during its private days, or investors may be losing interest because of lack of hype on MedReleaf.

Investor takeaway

While a further price decline on MedReleaf stock is possible, investors need to consider the upside potential, too.

The main reason for MedReleaf’s public listing was to raise expansion capital. It has managed to generate the most profits as a marijuana player in the country and has a methodical and professional management team that waited for confirmation of market growth forecasts before embarking on an ambitious and risky expansion program.

The company could outperform in the future if it manages to maintain its low production costs.

Momentum seems to be returning to marijuana stocks, and the “obscure” MedReleaf might still be yet to find favour from the skeptical investing public. The company’s relative underperformance may just be temporary.

Let’s wait and see how the market judges MedReleaf’s prospects going forward.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any stocks mentioned.

More on Investing

ETF chart stocks
Investing

Here Are My 2 Favourite ETFs for 2025

These are the ETFs I'll be eyeballing in the New Year.

Read more »

money goes up and down in balance
Dividend Stocks

This 6% Dividend Stock Is My Top Pick for Immediate Income

This Canadian stock has resilient business model, solid dividend payment and growth history, and a well-protected yield of over 6%.

Read more »

Canadian energy stocks are rising with oil prices
Energy Stocks

Outlook for Cenovus Energy Stock in 2025

A large-cap energy stock and TSX30 winner is a screaming buy for its bright business outlook and visible growth potential.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Stock Market

CRA: Here’s the TFSA Contribution Limit for 2025

The TFSA is a tax-sheltered account that allows you to hold diversified asset classes at a low cost.

Read more »

Hourglass and stock price chart
Tech Stocks

1 Canadian Stock Ready to Surge Into 2025

There is a lot of uncertainty about the market in general as we move closer to the following year, but…

Read more »

think thought consider
Stock Market

Billionaires Are Selling Apple Stock and Picking up This TSX Stock Instead

Billionaires like Warren Buffett continue to trim stakes in Apple stock, with others picking up this long-term stock instead.

Read more »

ways to boost income
Dividend Stocks

1 Excellent TSX Dividend Stock, Down 25%, to Buy and Hold for the Long Term

Down 25% from all-time highs, Tourmaline Oil is a TSX dividend stock that offers you a tasty yield of 5%…

Read more »

canadian energy oil
Energy Stocks

Is Baytex Energy Stock a Good Buy?

Baytex just hit a 12-month low. Is the stock now oversold?

Read more »